Skip to content

Intravenous Pantoloc In Aspirin-Induced Ulcer Bleeding

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00153725
Enrollment
156
Registered
2005-09-12
Start date
2003-02-28
Completion date
2006-09-30
Last updated
2006-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Cerebrovascular Disorders

Brief summary

The aim of the study is to investigate whether intravenous infusion of pantoprazole (Pantoloc) is effective in preventing recurrent bleeding in patients who present with acute ulcer bleeding and continue to use aspirin

Detailed description

Aspirin is an effective treatment for acute stroke and heart attack. However, aspirin also induces ulcer and provokes acute ulcer bleeding. Thus, aspirin is often withheld in acute ulcer bleeding but this precipitate recurrent stroke or heart attack. We previously showed that intravenous infusion of a potent acid suppressant substantially reduced the incidence of recurrent ulcer bleeding in patients who withheld aspirin. The aim of this study is to investigate whether intravenous infusion of an acid suppressant (Pantoprazole) is effective in preventing recurrent ulcer bleeding with continuous use of aspirin.

Interventions

DRUGAspirin and Pantoloc

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients received daily anti-platelet therapy for vascular prophylaxis before admission and will continue need to do so * Patinets with bleeding peptic ulcers;ulcer actively bleeding or with SRH (Forrest I, IIa and IIb ulcers) * Endoscopic haemostasis achieved

Exclusion criteria

* Presence of ulcer complication precluding endoscopic treatment such as gastric outlet obstruction or ulcer perforation mandating surgical intervention. * Concomitant use of anticoagulant, NSAIDs or steroid * Pending to undergo cardiac interventions that need double anti-platelet agent * Pregnancy * Terminal illness, or cancer

Design outcomes

Primary

MeasureTime frame
Primary Outcome:
Recurrent upper gastrointestinal bleeding within 30 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026